These findings align with more extensive analyses, such as a 2025 study (n = 88,273), which reported a 71% reduction in new heart failure diagnoses among cancer patients receiving anthracycline-based chemotherapy and SGLT2 inhibitors [157]. This evidence concerns the gene SLC5A2 and heart failure.